Trial reportOpen forum infectious diseases2026
Cryptococcal Meningitis: Comparison of Short- (≤ 1 Week) Versus Longer-duration (> 1 Week) Liposomal Amphotericin B Induction Therapy and Factors Associated With Clinical Outcomes in HIV and Non-HIV Patients.
Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Shorter induction regimens for cryptococcal meningitis (CM) are being proposed, but data from resource-rich countries are limited. We compared clinical outcomes between short- (≤ 1 week) and longer-duration (> 1 week) of liposomal amphotericin B (L-AmB) induction therapy and investigated factors associated with clinical outcomes at a United States medical center. Methods: In this retrospective study, cases of CM were identified by a positive cerebrospinal fluid (CSF) culture for Results: Of 129 patients, 20 were in the short-duration (11 patients with HIV) and 109 in the longer-duration L-AmB group (72 with HIV). The short-duration group was less severely ill at baseline. Unfavorable GOS at discharge was 50.0% versus 61.5% ( Conclusions: Short-duration L-AmB may have comparable outcomes to longer-duration in this cohort; further studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.